




Felbamate

Revised: September 21, 2020.

CASRN: 25451-15-4



Drug Levels and Effects

Summary of Use during Lactation

Because no information is available on the use of felbamate during breastfeeding, and because it can cause potentially fatal hematologic and hepatic toxicities, authors of authoritative reviews recommend that breastfeeding not be undertaken during maternal felbamate therapy until more safety data are available.[1,2]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Seizure Disorder) Carbamazepine, Divalproex, Gabapentin, Lamotrigine, Oxcarbazepine, Phenytoin, Valproic Acid

References

1. Bar-Oz B, Nulman I, Koren G, et al. Anticonvulsants and breastfeeding. A critical review. *Paediatr Drugs*. 2000;2:113–26. PubMed PMID: 10937463.
2. Hägg S, Spigset O. Anticonvulsant use during lactation. *Drug Saf*. 2000;22:425–40. PubMed PMID: 10877037.

Substance Identification

Substance Name

Felbamate

CAS Registry Number

25451-15-4

Drug Class

Breast Feeding

Lactation

Anticonvulsants